President and Chief Executive Officer
Craig A. Wheeler has served as our President and a director since August 2006 and was appointed our Chief Executive Officer effective September 2006. Prior to joining Momenta, Mr. Wheeler served as President of Chiron Biopharmaceuticals, a division of Chiron Corporation, a biotechnology company, from August 2001 until June 2006. Mr. Wheeler has been a member of the board of directors of Avanir Pharmaceuticals, Inc. since September 2005 and has served as chairman of the board since May 2007. Mr. Wheeler received B.S. and M.S. degrees in chemical engineering from Cornell University and an M.B.A. degree from the Wharton School of the University of Pennsylvania.
Senior Vice President, Human Resources
Ms. Beltramello joined Momenta in October of 2007. She was previously the Chief Human Resources Officer at Multiplan, a provider of health care cost management solutions with over 2,000 employees conducting business in all fifty states. In this role, she was responsible for all human resource operations, including strategy, policies and program development. Prior to joining Multiplan, she held senior human resources roles at Private Healthcare Systems, Inc., Oxford Global Resources, Inc., and Randstad North America.
Senior Vice President, Pharmaceutical Sciences
Vice President Program and Project Management
Mr. Fier joined Momenta in October of 2002. He was previously Vice President of Clinical Affairs at BioTransplant Inc. where he led a clinical development group responsible for the development and commercialization of both antibody-based therapeutics and medical devices. Prior to that, he held positions in product development and project management at Hoechst-Roussel (now Sanofi Aventis), Astra USA and The Medicines Company and was involved with the development and launch of several successful products. Mr. Fier received his BS from Tufts University and a MBA in Heath Care Management from Boston University.
Co-Founder, Chief Scientific Officer and Senior Vice President, Research
Dr. Kaundinya is one of Momenta's scientific founders. Prior to founding Momenta, Dr. Kaundinya was a member of the MIT faculty where he pioneered research in the area of analytical techniques for complex carbohydrates. He also served as the Director of Bioinformatics for the Consortium for Functional Glycomics, a multi-milliondollar NIH initiative to study the role of complex sugars in biology.
Vice President, Corporate Development and Strategy
Dr. Kwon joined Momenta in January of 2011. He was previously Senior Director of Business Development at Biogen Idec, where he led corporate development activities, including evaluation of mergers and acquisitions, joint ventures and other strategic transactions. Prior to that, he identified and invested in early-stage life science companies at Advanced Technology Ventures. He has co-authored numerous peer-reviewed publications in the area of neurobiology.
General Counsel, Senior Vice President and Secretary
Mr. Leicher joined Momenta in July of 2008. He was previously Senior Vice President and General Counsel at Altus Pharmaceuticals Inc. and also served as General Counsel and in senior legal positions at Antigenics Inc., Millennium Pharmaceuticals, Inc., Curis, Inc., Genetics Institute, Inc., and Wyeth. Mr. Leicher brings significant legal expertise in research and product development, product commercialization and launch, corporate finance and partnering transactions, intellectual property law and licensing, corporate governance and litigation. In private practice, he served as the Co-Chair of the Life Sciences Practice Group at Hill and Barlow and was an attorney at Hale and Dorr and Butler and Binion.
Chief Medical Officer and Senior Vice President, Development
Chief Financial Officer and Senior Vice President
Mr. Shea joined Momenta in October of 2003. He was previously Chief Operating Officer, Chief Financial Officer and Treasurer at Variagenics, Inc., a pharmacogenomics company, where he assisted in raising over $120 million, including a successful IPO. While at Variagenics, Mr. Shea was responsible for Finance, Legal, Investor Relations, Human Resources and Operations. Prior to this, Mr. Shea was Vice President of Finance at Genetics Institute, Inc. (now Wyeth), and a Senior Manager at PricewaterhouseCoopers.
Last revised 2/06/2013